Opioid Receptor Modulators via Hybrid Peptide Structures
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current opioid receptor modulators face challenges such as instability and adverse side effects, limiting their effectiveness in treating pain and gastrointestinal disorders, and there is a need for compounds that can selectively modulate mu, delta, and kappa receptors to provide improved pharmacological profiles.
Innovation Solution
Development of novel compounds of Formula (I) that include specific structural modifications allowing for selective modulation of opioid receptors, including mu, delta, and kappa receptors, which are designed to improve pharmacological profiles and reduce side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If simplified dipeptide structures are used to maintain opioid activity, then the molecular complexity is reduced, but the compound stability deteriorates
Solution Approach 1:
The patent combines peptide structures with non-peptide moieties to create hybrid compounds. Specifically, the invention uses N-acyl peptides where the acyl group contains heteroaromatic or heteroaliphatic nuclei, creating a composite structure that integrates the simplicity of truncated peptides with the stability of non-peptide components. This composite approach allows the molecule to maintain opioid receptor binding capability while improving metabolic stability and reducing susceptibility to enzymatic degradation.
2Reliability
If mu opioid agonist modulators are used to attenuate pain, then the analgesic efficacy is improved, but adverse side effects such as constipation, respiratory depression, and addiction potential increase
Solution Approach 1:
The patent introduces selectiveivity at specific regions of the molecule by incorporating particular heteroaromatic and heteroaliphatic nuclei in defined positions within the N-acyl group. This local structural differentiation allows the compound to exhibit preferential binding to specific opioid receptor subtypes (mu, delta, or kappa), thereby achieving targeted analgesic effects while minimizing activation of receptors that mediate adverse effects. The selective modulation of specific receptor subtypes enables differentiation between therapeutic and harmful outcomes.
Data Source
AI summary
The present invention is directed to novel opioid receptor modulators of Formula (I).The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.